SCHEMBL70537

SCHEMBL70537

O=C(O)c1cnncc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.46
ALDH1A1 P00352 5/20 0.45
ALOX15 P16050 2/20 0.45
CYP1A2 P05177 1/20 0.45
KDM4E B2RXH2 6/20 0.41
NAPRT Q6XQN6 3/20 0.41
MAPT P10636 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4C Q9H3R0 2/20 0.41
MEN1 O00255 1/20 0.41
KDM6B O15054 1/20 0.41
KDM4A O75164 1/20 0.41
THRB P10828 1/20 0.41
KDM4D Q6B0I6 1/20 0.41
ASPH Q12797 1/20 0.39
KDM8 Q8N371 1/20 0.39
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3523197 0.83 ALDH1A1 (0.42) HCAR2ALDH1A1ALOX15CYP1A2KDM4E
SCHEMBL29952027 0.81 KMT2A (0.54) HCAR2ALDH1A1ALOX15CYP1A2KDM4E
SCHEMBL5120215 0.81 KMT2A (0.54) HCAR2ALDH1A1ALOX15CYP1A2KDM4E
SCHEMBL29952809 0.81 GABRP (0.50) HCAR2ALDH1A1ALOX15CYP1A2KDM4E
SCHEMBL353823 0.81 GABRP (0.50) HCAR2ALDH1A1ALOX15CYP1A2KDM4E
SCHEMBL8828486 0.81 ALDH1A1 (0.44) HCAR2ALDH1A1ALOX15CYP1A2KDM4E
SCHEMBL14599182 0.77 IDO1 (0.40) HCAR2ALDH1A1ALOX15CYP1A2KDM4E
SCHEMBL4923887 0.75 ASPH (0.56) HCAR2ALDH1A1KDM4ENAPRTMAPT
SCHEMBL28302668 0.75 GABRP (0.39) HCAR2ALDH1A1ALOX15CYP1A2KDM4E
SCHEMBL22322535 0.74 HNF4A (0.50) ALDH1A1ALOX15GABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119836101-A Perovskite solar cell based on diamine molten salt surface modification and preparation method thereof 东方电气长三角(杭州)创新研究院有限公司 2025-04-15 CN claimed
CN-110643032-B Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2022-01-28 CN claimed
US-11142826-B2 Substitution-type electroless gold plating solution containing purine or pyrimidine-based compound having carbonyl oxygen and substitution-type electroless gold plating method using the same MK CHEM & TECH CO., LTD (KR) 2021-10-12 US claimed
CN-110923680-B Substituted electroless gold plating solution containing purine or pyrimidine compound having carbonyl oxygen and method using same MK化学科技有限公司 2021-09-24 CN claimed
CN-110923680-A Substituted electroless gold plating solution containing purine or pyrimidine compound having carbonyl oxygen and method using same MK化学科技有限公司 2020-03-27 CN claimed
US-20200095685-A1 SUBSTITUTION-TYPE ELECTROLESS GOLD PLATING SOLUTION CONTAINING PURINE OR PYRIMIDINE-BASED COMPOUND HAVING CARBONYL OXYGEN AND SUBSTITUTION-TYPE ELECTROLESS GOLD PLATING METHOD USING THE SAME MK CHEM & TECH CO., LTD (KR) 2020-03-26 US claimed
CN-110643032-A Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2020-01-03 CN claimed
CN-106967213-B Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2019-11-05 CN claimed
CN-108203252-B A kind of preparation method of slag micro powder 江苏润天建材有限公司 2018-11-02 CN claimed
CN-108203252-A A kind of preparation method of slag micro powder 江苏斯曼特新材料科技有限公司 2018-06-26 CN claimed
CN-106967213-A Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2017-07-21 CN claimed
CN-106925232-A For the modified pine branch adsorbent of Adsorption polymyxins 北京益净环保设备科技有限公司 2017-07-07 CN claimed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
EP-0332314-B1 SOLVENT EXTRACTION PROCESS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-12-23 EP claimed
US-4961856-A CONTACTING AQUEOUS SOLUTION CONTAINING PALLADIUM WITH SOLUTION OF SUBSTITUTED HETEROCYCLIC RING COMPOUND IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-10-09 US claimed
EP-0332314-A2 Solvent extraction process IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-09-13 EP claimed
EP-4590672-A1 PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 Merck Sharp & Dohme LLC (US) 2025-07-30 EP disclosed
EP-0112617-A1 Process for the extraction of metal values and novel metal extractants IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 HCAR2 45/4885ALDH1A1 1901/4885ALOX15 914/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA HCAR2 27/4885ALDH1A1 1510/4885ALOX15 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.